[{"quiz_id": "20251225T204141396Z_grok-4-0709_seed132", "question_id": "20251225T204141396Z_grok-4-0709_seed132-001", "question": "A 45-year-old man presents with progressive bilateral leg weakness, urinary incontinence, and episodic vertigo over 6 months. Examination reveals spastic paraparesis, upbeat nystagmus, and a positive Romberg sign. MRI shows T2 hyperintensities in the cerebellar peduncles and periventricular white matter. CSF analysis is normal except for elevated IgG index. What is the most likely diagnosis?", "options": ["Primary progressive multiple sclerosis", "Susac syndrome", "Behçet disease", "Neuromyelitis optica spectrum disorder", "Cerebrotendinous xanthomatosis"], "answer": "B", "answer_index": 1, "explanation": "Susac syndrome is characterized by the triad of encephalopathy, branch retinal artery occlusions, and sensorineural hearing loss, but can present with cerebellar involvement and white matter lesions mimicking multiple sclerosis. Primary progressive multiple sclerosis typically lacks the specific upbeat nystagmus and vertigo seen here, while Behçet disease often includes oral ulcers and uveitis, which are absent. Neuromyelitis optica spectrum disorder usually features optic neuritis or transverse myelitis with aquaporin-4 antibodies, not present in this case.", "generator_model": "grok-4-0709", "seed": 132, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Neurology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: The keyed answer (Susac syndrome) is incorrect; the best answer is A (Primary progressive multiple sclerosis). Key stem clues: 45-year-old man with progressive bilateral leg weakness (spastic paraparesis), urinary incontinence, episodic vertigo, upbeat nystagmus, positive Romberg, T2 hyperintensities in cerebellar peduncles and periventricular white matter, elevated CSF IgG index. These findings strongly support primary progressive MS: progressive myelopathy, cerebellar/brainstem involvement, periventricular white matter lesions, and elevated IgG index are classic. The rationale incorrectly claims Susac syndrome fits, but Susac's diagnostic triad (encephalopathy, branch retinal artery occlusions, hearing loss) is absent. The vignette provides no mention of retinal findings, hearing loss, or the characteristic \\\"snowball\\\" corpus callosum lesions of Susac. The rationale's dismissal of MS based on \\\"specific upbeat nystagmus and vertigo\\\" is medically inaccurate—both are well-documented in MS with brainstem involvement. NMOSD (D) is less likely without optic neuritis/longitudinally extensive transverse myelitis or AQP4 antibodies. Behçet (C) and CTX (E) lack supporting features. Minimal fix: Change the correct answer key from B to A, or add retinal/auditory findings to support Susac syndrome.\", \"medical_accuracy_score\": \"2\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: The keyed answer (Susac syndrome) is incorrect; the best answer is A (Primary progressive multiple sclerosis). Key stem clues: 45-year-old man with progressive bilateral leg weakness (spastic paraparesis), urinary incontinence, episodic vertigo, upbeat nystagmus, positive Romberg, T2 hyperintensities in cerebellar peduncles and periventricular white matter, elevated CSF IgG index. These findings strongly support primary progressive MS: progressive myelopathy, cerebellar/brainstem involvement, periventricular white matter lesions, and elevated IgG index are classic. The rationale incorrectly claims Susac syndrome fits, but Susac's diagnostic triad (encephalopathy, branch retinal artery occlusions, hearing loss) is absent. The vignette provides no mention of retinal findings, hearing loss, or the characteristic \"snowball\" corpus callosum lesions of Susac. The rationale's dismissal of MS based on \"specific upbeat nystagmus and vertigo\" is medically inaccurate—both are well-documented in MS with brainstem involvement. NMOSD (D) is less likely without optic neuritis/longitudinally extensive transverse myelitis or AQP4 antibodies. Behçet (C) and CTX (E) lack supporting features. Minimal fix: Change the correct answer key from B to A, or add retinal/auditory findings to support Susac syndrome.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251225T204141396Z_grok-4-0709_seed132", "question_id": "20251225T204141396Z_grok-4-0709_seed132-002", "question": "A 32-year-old woman with a history of atopic dermatitis develops widespread pruritic vesicles and bullae after starting a new biologic therapy. Biopsy shows subepidermal clefting with eosinophils and flame figures. Direct immunofluorescence is negative. What is the most appropriate next step in management?", "options": ["Switch to dupilumab", "Initiate dapsone therapy", "Administer rituximab", "Prescribe high-dose systemic corticosteroids", "Perform patch testing for contact allergens"], "answer": "B", "answer_index": 1, "explanation": "This presentation suggests bullous pemphigoid-like eruption induced by biologic therapy, but the flame figures and eosinophilic spongiosis point to eosinophilic cellulitis (Wells syndrome), which responds well to dapsone. Switching to dupilumab might exacerbate atopic conditions without addressing the eosinophilic component, while rituximab is reserved for refractory autoimmune bullous diseases. Systemic corticosteroids could provide temporary relief but are not first-line for this entity.", "generator_model": "grok-4-0709", "seed": 132, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Dermatology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The vignette describes a 32-year-old woman with atopic dermatitis developing pruritic vesicles/bullae after starting biologic therapy. Key findings: subepidermal clefting with eosinophils and flame figures, negative DIF. The stem creates diagnostic ambiguity. Subepidermal clefting with negative DIF suggests drug-induced bullous pemphigoid (BP) or BP-like eruption, where discontinuing the offending biologic and systemic corticosteroids (option D) are standard first-line management. However, the rationale pivots to Wells syndrome based on flame figures. This creates multiple defensible answers: (B) dapsone is reasonable for Wells syndrome or as steroid-sparing for BP; (D) systemic corticosteroids are first-line for both drug-induced BP and Wells syndrome. The stem doesn't provide sufficient discriminating features to definitively favor one diagnosis over the other. The rationale's dismissal of corticosteroids as 'not first-line for this entity' contradicts standard practice for both conditions. Medical accuracy issues: flame figures can occur in BP; Wells syndrome rarely presents with bullae; drug-induced BP typically requires corticosteroids first. Minimal fix: clarify the diagnosis by adding 'dermal flame figures without true bullae' to favor Wells syndrome, or remove flame figures to favor BP.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The vignette describes a 32-year-old woman with atopic dermatitis developing pruritic vesicles/bullae after starting biologic therapy. Key findings: subepidermal clefting with eosinophils and flame figures, negative DIF. The stem creates diagnostic ambiguity. Subepidermal clefting with negative DIF suggests drug-induced bullous pemphigoid (BP) or BP-like eruption, where discontinuing the offending biologic and systemic corticosteroids (option D) are standard first-line management. However, the rationale pivots to Wells syndrome based on flame figures. This creates multiple defensible answers: (B) dapsone is reasonable for Wells syndrome or as steroid-sparing for BP; (D) systemic corticosteroids are first-line for both drug-induced BP and Wells syndrome. The stem doesn't provide sufficient discriminating features to definitively favor one diagnosis over the other. The rationale's dismissal of corticosteroids as 'not first-line for this entity' contradicts standard practice for both conditions. Medical accuracy issues: flame figures can occur in BP; Wells syndrome rarely presents with bullae; drug-induced BP typically requires corticosteroids first. Minimal fix: clarify the diagnosis by adding 'dermal flame figures without true bullae' to favor Wells syndrome, or remove flame figures to favor BP.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251225T204141396Z_grok-4-0709_seed132", "question_id": "20251225T204141396Z_grok-4-0709_seed132-003", "question": "A 58-year-old man with incomplete tetraplegia from a C5 spinal cord injury undergoes functional electrical stimulation therapy. After 3 months, he develops shoulder pain and limited abduction. Imaging reveals heterotopic ossification around the glenohumeral joint. What is the most effective intervention to preserve joint mobility?", "options": ["Bisphosphonate therapy", "Low-dose radiation", "Surgical excision", "Indomethacin prophylaxis", "Passive range-of-motion exercises"], "answer": "B", "answer_index": 1, "explanation": "Low-dose radiation therapy is highly effective in preventing maturation of heterotopic ossification in spinal cord injury patients, preserving joint function without systemic side effects. Bisphosphonates like etidronate can inhibit mineralization but are less targeted and may cause gastrointestinal issues. Surgical excision is considered only after ossification matures and if function is severely impaired, not as a primary intervention.", "generator_model": "grok-4-0709", "seed": 132, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Physical Medicine and Rehabilitation", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - a different answer is more defensible. The stem describes established heterotopic ossification (HO) around the glenohumeral joint causing functional impairment (shoulder pain, limited abduction) after 3 months. Key discriminating findings: (1) HO already present on imaging, (2) symptomatic functional limitation, (3) C5 SCI patient. The question asks for intervention to \\\"preserve joint mobility\\\" in established HO. Low-dose radiation (option B, the key) is primarily a prophylactic measure used perioperatively or in early HO formation to prevent maturation - not standard treatment for established, symptomatic HO. Surgical excision (option C) is the definitive treatment for mature, symptomatic HO causing functional impairment, typically performed after maturation (6-12 months) with perioperative prophylaxis. Bisphosphonates and NSAIDs are prophylactic, not therapeutic for established HO. Passive ROM alone is insufficient for established ossification. The timing (3 months) suggests early but established HO; however, the presence of functional impairment and imaging-confirmed HO makes surgical planning more appropriate than radiation alone. Medical accuracy issue: radiation is prophylactic, not therapeutic for established symptomatic HO. Minimal fix: clarify timing as \\\"at risk for HO\\\" or \\\"early HO formation\\\" to justify radiation, or change key to C if HO is mature and symptomatic.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - a different answer is more defensible. The stem describes established heterotopic ossification (HO) around the glenohumeral joint causing functional impairment (shoulder pain, limited abduction) after 3 months. Key discriminating findings: (1) HO already present on imaging, (2) symptomatic functional limitation, (3) C5 SCI patient. The question asks for intervention to \"preserve joint mobility\" in established HO. Low-dose radiation (option B, the key) is primarily a prophylactic measure used perioperatively or in early HO formation to prevent maturation - not standard treatment for established, symptomatic HO. Surgical excision (option C) is the definitive treatment for mature, symptomatic HO causing functional impairment, typically performed after maturation (6-12 months) with perioperative prophylaxis. Bisphosphonates and NSAIDs are prophylactic, not therapeutic for established HO. Passive ROM alone is insufficient for established ossification. The timing (3 months) suggests early but established HO; however, the presence of functional impairment and imaging-confirmed HO makes surgical planning more appropriate than radiation alone. Medical accuracy issue: radiation is prophylactic, not therapeutic for established symptomatic HO. Minimal fix: clarify timing as \"at risk for HO\" or \"early HO formation\" to justify radiation, or change key to C if HO is mature and symptomatic.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251225T204141396Z_grok-4-0709_seed132", "question_id": "20251225T204141396Z_grok-4-0709_seed132-004", "question": "A 67-year-old woman with a history of migraine presents with acute onset of hemianopia, ataxia, and confusion. CT angiography shows occlusion of the posterior inferior cerebellar artery with extension into the basilar artery. Despite thrombolysis, she deteriorates with locked-in syndrome. What rare complication is most likely responsible for this progression?", "options": ["Reperfusion injury", "Basilar artery dissection", "Paradoxical embolism", "Top-of-the-basilar syndrome", "Intracranial atherosclerotic disease"], "answer": "C", "answer_index": 2, "explanation": "Paradoxical embolism through a patent foramen ovale can cause extension of infarction in vertebrobasilar territory, leading to locked-in syndrome despite initial thrombolysis. Reperfusion injury typically manifests as hemorrhage, not progression of ischemia, while basilar artery dissection would show characteristic imaging findings not described. Top-of-the-basilar syndrome involves thalamic and midbrain infarction but lacks the cerebellar involvement here.", "generator_model": "grok-4-0709", "seed": 132, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Neurology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - a different answer is more defensible. The stem describes PICA occlusion with extension into the basilar artery causing locked-in syndrome despite thrombolysis. Key discriminating findings: initial PICA territory stroke, progression to basilar involvement, locked-in syndrome post-thrombolysis. Locked-in syndrome results from ventral pontine infarction due to basilar artery occlusion. The keyed answer (C, paradoxical embolism) is implausible: paradoxical embolism is a mechanism of initial stroke, not a complication of progression post-thrombolysis; the stem already describes established arterial occlusion on CTA. Option D (top-of-the-basilar syndrome) better explains progression: it describes rostral basilar territory infarction affecting thalamus/midbrain/occipital lobes, consistent with hemianopia and confusion, and can progress to involve the entire basilar territory including ventral pons (locked-in). The rationale incorrectly states top-of-the-basilar lacks cerebellar involvement, but the question asks what caused PROGRESSION to locked-in, not the initial PICA stroke. Option B (basilar dissection) is also defensible as a complication causing progression. Medical accuracy issue: paradoxical embolism cannot explain post-thrombolysis deterioration in already-occluded vessels. Minimal fix: Change key to D or rewrite stem to describe a mechanism question about the initial stroke rather than a complication of progression.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - a different answer is more defensible. The stem describes PICA occlusion with extension into the basilar artery causing locked-in syndrome despite thrombolysis. Key discriminating findings: initial PICA territory stroke, progression to basilar involvement, locked-in syndrome post-thrombolysis. Locked-in syndrome results from ventral pontine infarction due to basilar artery occlusion. The keyed answer (C, paradoxical embolism) is implausible: paradoxical embolism is a mechanism of initial stroke, not a complication of progression post-thrombolysis; the stem already describes established arterial occlusion on CTA. Option D (top-of-the-basilar syndrome) better explains progression: it describes rostral basilar territory infarction affecting thalamus/midbrain/occipital lobes, consistent with hemianopia and confusion, and can progress to involve the entire basilar territory including ventral pons (locked-in). The rationale incorrectly states top-of-the-basilar lacks cerebellar involvement, but the question asks what caused PROGRESSION to locked-in, not the initial PICA stroke. Option B (basilar dissection) is also defensible as a complication causing progression. Medical accuracy issue: paradoxical embolism cannot explain post-thrombolysis deterioration in already-occluded vessels. Minimal fix: Change key to D or rewrite stem to describe a mechanism question about the initial stroke rather than a complication of progression.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251225T204141396Z_grok-4-0709_seed132", "question_id": "20251225T204141396Z_grok-4-0709_seed132-005", "question": "A 28-year-old man presents with erythematous plaques on the trunk and extremities that worsen with sun exposure. Biopsy reveals interface dermatitis with vacuolar degeneration and apoptotic keratinocytes. Serology shows positive anti-Ro/SSA antibodies. Despite hydroxychloroquine, lesions persist. What is the most appropriate adjunctive therapy?", "options": ["Thalidomide", "Mycophenolate mofetil", "Intravenous immunoglobulin", "Lenalidomide", "Apremilast"], "answer": "A", "answer_index": 0, "explanation": "This is subacute cutaneous lupus erythematosus, and thalidomide is effective for refractory cases with photosensitivity and anti-Ro positivity due to its anti-angiogenic and immunomodulatory effects. Mycophenolate mofetil is more suited for systemic lupus but less effective for cutaneous-limited disease. Intravenous immunoglobulin is reserved for severe systemic involvement, not primarily cutaneous manifestations.", "generator_model": "grok-4-0709", "seed": 132, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Dermatology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 28-year-old man with photosensitive erythematous plaques, interface dermatitis with vacuolar degeneration, apoptotic keratinocytes, and positive anti-Ro/SSA antibodies—classic findings for subacute cutaneous lupus erythematosus (SCLE). The patient has failed first-line hydroxychloroquine therapy. Key discriminating findings: refractory cutaneous lupus with photosensitivity and anti-Ro positivity. Thalidomide (A) is well-established as highly effective adjunctive therapy for refractory cutaneous lupus, particularly SCLE, with strong evidence supporting its use despite teratogenicity concerns requiring strict monitoring. Mycophenolate mofetil (B) is primarily used for systemic lupus with renal/organ involvement, less effective for isolated cutaneous disease. IVIG (C) is reserved for severe systemic manifestations or life-threatening complications, not refractory cutaneous-limited disease. Lenalidomide (D) and apremilast (E) lack robust evidence for refractory SCLE compared to thalidomide. The keyed answer is medically accurate and represents standard practice for this clinical scenario. No logical flaws or medical inaccuracies identified. Minimal fix: None needed; item is valid as written.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 28-year-old man with photosensitive erythematous plaques, interface dermatitis with vacuolar degeneration, apoptotic keratinocytes, and positive anti-Ro/SSA antibodies—classic findings for subacute cutaneous lupus erythematosus (SCLE). The patient has failed first-line hydroxychloroquine therapy. Key discriminating findings: refractory cutaneous lupus with photosensitivity and anti-Ro positivity. Thalidomide (A) is well-established as highly effective adjunctive therapy for refractory cutaneous lupus, particularly SCLE, with strong evidence supporting its use despite teratogenicity concerns requiring strict monitoring. Mycophenolate mofetil (B) is primarily used for systemic lupus with renal/organ involvement, less effective for isolated cutaneous disease. IVIG (C) is reserved for severe systemic manifestations or life-threatening complications, not refractory cutaneous-limited disease. Lenalidomide (D) and apremilast (E) lack robust evidence for refractory SCLE compared to thalidomide. The keyed answer is medically accurate and represents standard practice for this clinical scenario. No logical flaws or medical inaccuracies identified. Minimal fix: None needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251225T204141396Z_grok-4-0709_seed132", "question_id": "20251225T204141396Z_grok-4-0709_seed132-006", "question": "A 42-year-old woman with rheumatoid arthritis and secondary fibromyalgia undergoes multidisciplinary pain management. She reports persistent widespread pain despite optimized pharmacotherapy. Quantitative sensory testing shows central sensitization. What advanced rehabilitation technique is most likely to provide long-term benefit?", "options": ["Graded motor imagery", "Transcutaneous electrical nerve stimulation", "Aquatic therapy", "Cognitive behavioral therapy alone", "Spinal cord stimulation"], "answer": "A", "answer_index": 0, "explanation": "Graded motor imagery effectively addresses central sensitization in fibromyalgia by reprogramming cortical representations, leading to sustained pain reduction in rheumatoid arthritis overlap. Transcutaneous electrical nerve stimulation provides short-term relief but does not target central mechanisms. Spinal cord stimulation is invasive and indicated for neuropathic pain, not widespread fibromyalgia pain.", "generator_model": "grok-4-0709", "seed": 132, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Physical Medicine and Rehabilitation", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a 42-year-old woman with RA and secondary fibromyalgia, persistent widespread pain despite optimized pharmacotherapy, and central sensitization on quantitative sensory testing. The question asks for the advanced rehabilitation technique most likely to provide long-term benefit. Key issue: Multiple options target central sensitization and have evidence for long-term benefit in fibromyalgia. Graded motor imagery (GMI) has emerging evidence but is not established as superior to cognitive behavioral therapy (CBT) for fibromyalgia with central sensitization. CBT has robust, well-established evidence for long-term benefit in fibromyalgia and directly addresses central pain processing through cognitive restructuring and behavioral modification. The rationale dismisses CBT as 'alone' (implying it's insufficient), but the stem doesn't indicate CBT has been tried or failed. Both GMI and CBT are defensible as best answers for long-term benefit in central sensitization. The item also contains a medical accuracy issue: GMI is not widely recognized as a first-line or superior intervention for fibromyalgia compared to CBT in major guidelines. Minimal fix: Specify that CBT has been tried without adequate benefit, or clarify that the question seeks a motor-based intervention specifically.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a 42-year-old woman with RA and secondary fibromyalgia, persistent widespread pain despite optimized pharmacotherapy, and central sensitization on quantitative sensory testing. The question asks for the advanced rehabilitation technique most likely to provide long-term benefit. Key issue: Multiple options target central sensitization and have evidence for long-term benefit in fibromyalgia. Graded motor imagery (GMI) has emerging evidence but is not established as superior to cognitive behavioral therapy (CBT) for fibromyalgia with central sensitization. CBT has robust, well-established evidence for long-term benefit in fibromyalgia and directly addresses central pain processing through cognitive restructuring and behavioral modification. The rationale dismisses CBT as 'alone' (implying it's insufficient), but the stem doesn't indicate CBT has been tried or failed. Both GMI and CBT are defensible as best answers for long-term benefit in central sensitization. The item also contains a medical accuracy issue: GMI is not widely recognized as a first-line or superior intervention for fibromyalgia compared to CBT in major guidelines. Minimal fix: Specify that CBT has been tried without adequate benefit, or clarify that the question seeks a motor-based intervention specifically.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}]